Table 1 Baseline characteristics of patients
Variable | Thalidomide/prednisone | Thalidomide/prednisone/danazol | P-value |
|---|---|---|---|
No. | 46 | 42 | |
Age (years) | 53 (21, 77) | 53 (26, 72) | 0.776 |
Male n (%) | 24 (52.2%) | 22 (52.3%) | 0.985 |
Previous therapy | 13 (28.3%) | 18 (42.9%) | 0.152 |
Spleen size below left costal margin (cm) | 3 (0,18) | 5 (0, 24) | 0.606 |
Constitutional symptoms | 18 (39.1%) | 11 (26.2%) | 0.197 |
Hemoglobin (g/L) | 71 (31, 99) | 71 (38, 99) | 0.854 |
WBC counts (×109/L) | 4.07 (0.75, 22.36) | 3.22 (1.51, 25.63) | 0.335 |
Platelets counts(×109/L) | 100 (3, 1064) | 80 (14, 540) | 0.631 |
Serum EPO (mU/mL) | 504 (21, 774) | 652 (76, 774) | 0.845 |
RBC transfusion dependency | 20 (43.5%) | 18 (42.9%) | 0.953 |
Blood blasts% | 0 (0,17) | 0 (0, 2) | 0.100 |
Marrow blasts% | 0 (0,7) | 0 (0,5) | 0.202 |
Bone marrow fibrosis | 0.328 | ||
MF-2 | 35 (76.1%) | 28 (66.7%) | |
MF-3 | 11 (23.9%) | 14 (33.3%) | |
Cytogeneticsa | 0.777 | ||
Unfavorable | 9 (27.3%) | 5 (23.8%) | |
Favorable | 24 (72.7%) | 16 (76.2%) | |
JAK2V6A7F mutationb | 0.810 | ||
Positive | 16 (46%) | 15 (43%) | |
Negative | 19 (54%) | 20 (57%) | |
DIPSS risk group | 0.217 | ||
Intermediate-1 | 20 (43.5%) | 25 (59.5%) | |
Intermediate-2 | 22 (47.8%) | 16 (38.1%) | |
High | 4 (8.7%) | 1 (2.4%) |
